Impact of Canine Mediation Practice in Psychomotor Therapy on Improving the Quality of Life in Adult Epileptic Patients.
MCP-Epi
1 other identifier
interventional
76
0 countries
N/A
Brief Summary
In addition to the search for new pharmaceutical or surgical solutions that could improve the therapeutic management of epileptic individuals, it is interesting to ask whether other complementary approaches, such as canine mediation in psychomotor therapy, could enhance the quality of life in this population. However, there is currently no evidence indicating that exposure to animals through mediation sessions would be beneficial for epileptic individuals, particularly regarding their quality of life, anxiety, emotional management, or cognition (such as social cognition). In the absence of current data in this population, it seems pertinent to study the impact of this practice on people with epilepsy. Furthermore, beyond quality of life, it would be valuable to examine whether it also influences anxiety or the frequency of seizures in individuals with epilepsy (a phenomenon reported for epileptic individuals living with a pet dog or a service dog). Canine mediation could help better manage and regulate the emotions of epileptic individuals, as well as improve their self-esteem.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2026
Longer than P75 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 21, 2025
CompletedFirst Posted
Study publicly available on registry
March 27, 2025
CompletedStudy Start
First participant enrolled
January 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2029
December 17, 2025
October 1, 2025
3.4 years
March 21, 2025
December 9, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Improvement of quality of life
Increase in the Quality of Life in Epilepsy Inventory-31 (QOLIE-31) score of at least 5 points between inclusion and one week after the completion of the 10 sessions. The score of the QOLIE-31 (Quality of Life in Epilepsy Inventory-31) ranges from 0 to 100. A score of 0 represents the worst possible quality of life, while a score of 100 represents the best possible quality of life.
Day 0 and Day 7 after the end of the 10 sessions
Study Arms (2)
canine mediation in psychomotor therapy
EXPERIMENTALGroup psychomotor therapy sessions combined with canine mediation (1 session per week for 10 weeks)
standard psychomotor therapy
ACTIVE COMPARATORStandard group psychomotor therapy sessions (1 session per week for 10 weeks)
Interventions
Animal mediation consists of bringing an animal into contact with a specific audience to improve the mental or physical health of a person. The dog and beneficiaries interact through various activities, in which the animal participates, offered during the sessions. The dog plays a particularly important role as a mediator through the bonds it forms with the human, as well as a non-judgmental partner in interaction. The canine educator will be accompanied by a healthcare professional during interventions. The sessions are organized based on the expertise and suggestions of both professions (canine educator and psychomotor therapist). The canine educator will be a state-certified professional educator with a specialization in animal mediation. The dog used is trained by the educator, with two types of learning being worked on: emotions and "commands" on cue.
standard sessions of psychomotor therapy
Eligibility Criteria
You may qualify if:
- Person aged ≥ 18 years
- Presenting pharmacoresistant epilepsy according to the criteria of the International League Against Epilepsy
- Requiring psychomotor therapy sessions for one of the following indications:
- Difficult emotional and relational management And/or global motor difficulties And/or body schema organization disorder And/or temporo-spatial disorder
- Explicit consent or no opposition to participation in the study by the patient and/or their legal representative or guardian
- Image rights consented by the patient and their legal representative or guardian, if applicable
- Hospitalization or residence at the Teppe Institute or at the FAM (Foyer d'Accueil Médicalisé) des 4 Jardins planned for at least 3 months
- Affiliated with or a beneficiary of a social security scheme
You may not qualify if:
- Fear or phobia of dogs
- Epileptic person benefiting from a legal protection measure other than guardianship or curatorship
- Person with insufficient cognitive abilities to respond to the questionnaires
- Pregnant or breastfeeding woman
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 21, 2025
First Posted
March 27, 2025
Study Start
January 1, 2026
Primary Completion (Estimated)
June 1, 2029
Study Completion (Estimated)
June 1, 2029
Last Updated
December 17, 2025
Record last verified: 2025-10